For link to original source, please click here.

For link to full article, please click here.

For link to full article, please click here.  

For link to full article, please click here.

For link to full article, please click here.

For link to full article, please click here.

Caladrius’ Vice President of Global Regulatory Affairs, William Sietsema, discusses the global regulatory environment for regenerative medicines and the Company’s priority review designations in the U.S. […]

Caladrius Biosciences selected as BioNJ’s Emerging Company in the Spotlight

FutureTech Podcast featuring Douglas W. Losordo, MD, FACC, FAHA, Executive Vice President, Global Head of Research and Development, Caladrius Biosciences – Cells, Tissue, and Repair

Clinical Leader’s Chief Editor, Ed Miseta, on Caladrius’ type 1 diabetes product candidate, CLBS03, progress through its phase 2 clinical trial.

BioWorld highlights Caladrius’ Sanford Project: T-Rex Study and upcoming milestones.

MD Magazine discusses CLBS03 halfway through enrollment in the Sanford Project: Trex Study with Kurt Grifin, MD, PhD, director of clinical trials for the Sanford Project.

Juvenile Diabetes Cure Alliance details previous CLBS03 study results and how the T regulatory cell technology works.

Close Concerns highlights Caladrius’s CLBS03 product candidate for the recent onset of type 1 diabetes in adolescence and the $12.2 million grant the program received from the California Institute for Regenerative Medicine (CIRM).

Caladrius Chief Executive Officer, Dr. David Mazzo, sits down with CEOCFO Magazine to discuss the Company’s cell therapy development pipeline and CDMO capabilities.

Caladrius Chief Executive Officer, Dr. David Mazzo, discusses the Company’s cell therapy development and CDMO capabilities with Stock News Now’s Shelly Kraft at the Aegis 2016 Growth Conference in Las Vegas.

Caladrius Biosciences recently announced that its product candidate CLBS03 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of type 1 diabetes mellitus (TID), making it the first known therapeutic candidate for T1D to receive the designation.

Caladrius Biosciences has received FDA orphan drug designation for its CLBS03 therapy for people with type 1 diabetes who still have some residual beta cell function.